

family members. However, clinical presentation was consistent with neurovisceral porphyria, no alternative causes were present for the expressive elevation of PBG and porphyrins, and a *CPOX* variant was found.

To the best of our knowledge, two other cases of SLE and hereditary coproporphyria have been reported.^{2,3} This association is most likely fortuitous, considering the low number of reports and weak evidence for shared pathological mechanisms. On the other hand, both entities present mainly in women of childbearing age, and can be precipitated by external factors. In the present case, pregnancy was likely the common factor precipitating flares of both SLE and HCP, although it is an infrequent precipitant for the latter.⁴ An SLE flare could precipitate a porphyric attack through caloric deprivation, but the presenting abdominal symptoms and dysautonomia were likely porphyric. In addition, drugs used to treat SLE could have aggravated the porphyria, since methylprednisolone, cyclophosphamide, and hydroxy-chloroquine are all possibly porphyrinogenic.⁵

Though acute porphyrias are rare disorders, one study found a surprisingly high prevalence of 11% previously undiagnosed cases in patients with acute polyneuropathy or encephalopathy in combination with abdominal pain or dysautonomic features.⁶

Our case highlights the necessity of including porphyria in the differential diagnosis of an acute polyneuropathy, even when alternative causes are present. The availability of specific therapy and preventive measures has important clinical implications, not only for the patient but also to family members, since without prompt treatment recovery is unpredictable and often incomplete.

Conflict of interest

The authors declare no conflicts of interest and no disclosures relevant to the manuscript. Informed consent was obtained from the patient for publication of this case report.

Acknowledgements

The authors wish to thank Dr. Estela Nogueira, from the Nephrology Department, and Dr. Catarina Resende, from the

Rheumatology Department, for their expertise and assistance in the present case.

References

- Stein PE, Badminton MN, Rees DC. Update review of the acute porphyrias. *Br J Haematol*. 2017;176:527–38, <http://dx.doi.org/10.1111/bjh.14459>.
- Korkmaz C. Delayed diagnosis of porphyria based on manifestations of systemic lupus erythematosus and ankylosing spondylitis. *J Nephrol*. 2006;19:535–9.
- Alioua C, Patel A, Bakir AA. Co-existence of systemic lupus erythematosus and severe hepatic porphyria. *Nephrol Dial Transplant*. 1999;14:2944–6, <http://dx.doi.org/10.1093/ndt/14.12.2944>.
- Brodie MJ, Moore MR, Thompson GG, Goldberg A, Low RAL. Pregnancy and the acute porphyrias. *Br J Obstet Gynaecol*. 1977;84:726–31, <http://dx.doi.org/10.1111/j.1471-0528.1977.tb12480.x>.
- The Drug Database for Acute Porphyria. Available from: <http://www.drugs-porphyria.org/> [accessed 05.01.21].
- Pischik E, Kazakov V, Kauppinen R. Is screening for urinary porphobilinogen useful among patients with acute polyneuropathy or encephalopathy? *J Neurol*. 2008;255:974–9, <http://dx.doi.org/10.1007/s00415-008-0779-9>.

S. Parreira^{a,*}, P.F. Viana^{b,c}, A.P. Antunes^a,
L. Albuquerque^{a,b}

^a *Neurology Department, Department of Neurosciences and Mental Health, Hospital de Santa Maria – Centro Hospitalar Lisboa Norte, Avenida Professor Egas Moniz, Lisboa, Portugal*

^b *Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, Lisboa, Portugal*

^c *Department of Basic & Clinical Neuroscience, King's College London, London, United Kingdom*

* Corresponding author.

E-mail address: sara.b.parreira@gmail.com (S. Parreira).

<https://doi.org/10.1016/j.nrl.2021.02.005>
2173-5808/

© 2021 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Recurrent intracranial hemorrhage in a patient with relapsing multiple sclerosis under interferon-β therapy

Hemorragia intracraneal recurrente en una paciente con Esclerosis Múltiple y tratamiento con Interferon-β

Dear Editor,

Interferon-β (IFN-β) is an immunomodulatory agent that has been used for the treatment of multiple sclerosis (MS) for



more than twenty years now. Its efficacy and tolerability are well known as well as its side effects.¹ We present a case of a woman diagnosed of relapsing-remitting multiple sclerosis (RRMS) who developed two spontaneous intracranial hemorrhage (ICH) while on subcutaneous IFN-β-1b and intramuscular IFN-β-1a.

A 56-year-old woman smoker of 10 cigarettes per day otherwise healthy, was diagnosed of RRMS in 2006 due to a left hemi-hypoesthesia relapse, three periventricular, two subcortical and an infratentorial lesion in a brain Magnetic Resonance Imaging (MRI) and positive IgG oligoclonal bands in cerebrospinal fluid. She had been treated with subcutaneous IFN-β-1b 250 µg every two days for eight years. She suffered a new relapse (transverse myelitis) in




Figure 1 (a) CT brain (2014) showing right frontal hemorrhage and subarachnoid hemorrhage around temporal lobe. (b) Gradient Echo T2 sequence one month later showing hypointense signal around temporal lobe due to subarachnoid hemorrhage and around right frontal hemorrhage. No hypointense signals suggestive of microbleeds are shown. (c) High signal lesions on axial FLAIR-T2 sequence one month later showing juxtacortical and periventricular lesions suggestive of MS diagnosis. (d) CT brain (2019) showing left frontal hemorrhage, subarachnoid hemorrhage around frontal and temporal lobe, and mass effect.

2009, with complete symptoms resolution. She was admitted to Emergency Department (ED) due to status epilepticus in February 2014. No prior history of head trauma was reported. A brain Computed Tomography (CT) showed a right frontal hematoma (24 mm × 28 mm × 32 mm) (Fig. 1a). She was transferred to Intensive Care Unit where she needed orotracheal intubation, sedation and antiepileptic treatment.

Initial blood pressure was 127/72 mmHg. Routine laboratory tests and drugs in urine were normal on admission. An extensive coagulopathy panel, including platelet count and function tests, coagulation times, and hemorrhagic diathesis was uninformative. Serologies were also negative. A cerebral angiography did not find any aneurysm, arterial or venous malformations. A brain MRI did not show any underlying vascular abnormality, signs of vasculitis, brain tumor or cerebral microbleeds one month later (Fig. 1b and c). Brain biopsy was not performed. The patient did not have any personal or familial history of spontaneous bleeding, nor during minor surgeries. She did not have history of cognitive impairment or other vascular risk factors apart from smoking. The patient recovered appropriately and no neurosurgical treatment was needed.

In August 2014, IFN β was switched to subcutaneous glatiramer acetate (20 mg/day) and then discontinued in November 2014 because of dermatological side effects. In December 2014, intramuscular IFN- β -1a (30 μ g per week) was started. By that time, the patient had been without disease activity and had a score of 2.5 in the Expanded Disability Status Scale (EDSS). Follow up MRI (2016 and 2018) did not find disease activity, nor found them any cerebral microbleeds.

In April 2019, she suffered a new left motor and sensitive relapse. Blood and urine analysis did not find any abnormality and urgent CT did not show any new finding. She was treated with intravenous methylprednisolone 1 g daily for five days. The day after finishing this treatment, she was admitted to ED complaining of headache and somnolence. Blood pressure was 150/90 mmHg. Brain CT showed a left frontal intracerebral hemorrhage with mass effect (Fig. 1d) without contrast enhancement or venous thrombosis signs. Urgent left frontal craniotomy was performed. An extensive investigation for coagulopathy was repeated, but it was unnoticeable again.

In January 2020, EDSS score was 3.5 (right pyramidal signs, right leg weakness and left hemi-hypoesthesia). An

extensive neuropsychological study found mild amnesic cognitive impairment and low quality of life assessment. Since the patient suffered two spontaneous intracerebral hemorrhages while on interferon- β therapy without any other potential cause, we might consider the possible relationship between interferon- β and recurrent ICHs in this patient.

Interferon- β is a natural cytokine secreted in response to pathogens and other substances. It is claimed that it has immunomodulatory, antiviral, antitumoral and anti-inflammatory effects.² It exerts them via different mechanisms such as the prevention of migration of leukocytes across the blood-brain-barrier or by modifying antigen presentation,³ but it has also effects on endothelial cells as shown in cancer or during viral infections.⁴

ICHs in MS patients are uncommon, may occur generally in patients with previous vascular risk factors. Moreover, patients under disease modifying therapy might have a trend against ICH.⁵ A review of the literature found only two cases similar to our patient: two women on interferon- β -1b for MS. One of them, like ours, suffered an ICH while on treatment with methylprednisolone for a MS relapse,⁶ and the other, suffered two spontaneous and bilateral ICHs within four days⁷ without concomitant corticosteroid therapy, as first ICH suffered by our patient. It is noticeable that interferon- β has been linked to thrombotic microangiopathy, Raynaud Phenomenon or pulmonary arterial hypertension, suggesting a procoagulant and vasoconstrictive effect, probably related to an impairment in endothelial cell functions, as shown in vitro.^{8,9} There are also reports of severe bleedings in other organs in patients under interferon- β therapy^{10,11} and of an increase in cardiovascular risk.¹²

In the case we present, common factors for ICH, except smoking, were absent and ICH common and uncommon causes were also ruled out. It has been recently shown that patients with MS have a higher risk of hemorrhagic stroke compared to non-MS population, specially within the first five years after MS diagnosis.¹³ Exposure to a specific MS treatment was not considered in that meta-analysis. Since it is strikingly rare that two spontaneous ICHs occur in the same patient in the absence of an underlying disorder, we cannot preclude a potential relation to Interferon- β in our patient's context. If a patient with MS under Interferon- β therapy suffers a hemorrhagic event and alternative causes are excluded, Interferon- β discontinuation might be considered. As far as we as concerned, this would be the third case published of ICH in a patient with MS under

IFN- β treatment. More studies are warranted to evaluate the possible relationship between the drug and this severe complication.

Funding

Authors do not receive any funding for this paper.

Conflict of interest

Authors do not have any conflicts of interest to disclose associated with this publication.

References

1. Nikfar S, Rahimi R, Abdollahi M. A meta-analysis of the efficacy and tolerability of interferon-B in multiple sclerosis overall and by drug and disease type. *Clin Ther*. 2010;32.
2. Abdolvahab MH, Mofrad MRK, Schellekens H. Interferon beta: from molecular level to therapeutic effects. *Int Rev Cell Mol Biol*. 2016;326:346–72.
3. Zettl U, Hecker M, Aktas O, Wagner T, Rommer P. Interferon B-1a and B-1b for patients with multiple sclerosis: updates to current knowledge. *Expert Rev Clin Immunol*. 2018;14: 137–53.
4. Phanthanawiboon S, Limkittikul K, Sakai Y, Takakura N, Saijo M, Kurosu T. Acute systemic infection with dengue virus leads to vascular leakage and death through tumor necrosis factor- α and Tie2/angiopoietin signaling in mice lacking type I and II interferon receptors. *PLOS ONE*. 2016;11.
5. Zulfiqar M, Queadan F, Ikram A, Farooqui M, Richardson SP, Calder CS, et al. Intracerebral haemorrhage in multiple sclerosis: a retrospective cohort study. *J Stroke Cerebrovasc Dis*. 2019;28:267–75.
6. Niedrwiessner G, Bonelli RM, Kammerhuber F, Reisecker F, Köllinger P. Intracerebral haemorrhage under interferon-beta therapy. *Eur J Neurol*. 2001;8:363–4.
7. Shahmohammadi S, Mohammadianinejad SE, Sahraian MA, Moghadasi AN. Intracerebral hemorrhage in a patient with multiple sclerosis receiving interferon beta-1a. *Arch Neurosci*. 2017;4.
8. Ben-Amor T, Trochanov A, Fischer T. Cumulative review of thrombotic microangiopathy thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome reports with subcutaneous interferon β -1a. *Adv Ther*. 2015;32:445–54.
9. Rot U, Ledinek AH. Interferons beta have vasoconstrictive and procoagulant effects: a woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis. *Clin Neurol Neurosurg*. 2013;115:579–81.
10. Gaetani L, Menduno PS, Cometa F, Di Gregorio M, Sarchielli P, Cagini C. Retinopathy during interferon-B treatment of multiple sclerosis: case report and review of the literature. *J Neurol*. 2016;263:422–7.
11. Pakulski LA, Di Marco LM. Severe vaginal bleeding associated with recombinant interferon beta-1B. *Ann Pharmacother*. 1997;31:50–2.
12. Sternberg Z, Leung C, Stenberg D, Yu J, Hojnacki D. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis. *Cardiovasc Ther*. 2014;32:33–9.
13. Hong Y, Tang H, Ma M, Chen N, Xie X, He L. Multiple sclerosis and stroke: a systematic review and meta-analysis. *BMC Neurol*. 2019;19:139.

A. Sánchez-Soblechero*, J.P. Cuello, M.L. Martínez Ginés, A. Lozano Ros, F. Romero Delgado, C. De Andrés, H. Goicochea Briceño, J.M. García Domínguez
Department of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

* Corresponding author.

E-mail address: antonio.sanchez.s@hotmail.com (A. Sánchez-Soblechero).

<https://doi.org/10.1016/j.nrl.2021.02.002>

2173-5808/

© 2021 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Reduction of photoparoxysmal response from patients with drug-resistant photosensitive epilepsy by using Z1 filters

Reducción de la respuesta fotoparoxística en pacientes con epilepsia fotosensible farmacorresistente mediante el uso de filtros Z1

Dear Editor,

Reflex epilepsy is characterized by seizures triggered by a specific stimulus. Photosensitive epilepsy (PSE) has seizures provoked by photic stimuli. PSE is the most common form of reflex epilepsy and affects 2–5% of patients with epilepsy. The main feature is photosensitivity, which is an abnormal

paroxysmal electrical reaction in the brain induced by strobe lights. The photoparoxysmal response (PPR) is the appearance of epileptiform activity induced by intermittent photic stimulation (IPS).^{1,2}

Capovilla G et al, have demonstrated that Z1-filter, was more effective than four other colored types of lenses in reducing the response to IPS in PSE patients.³ These results were confirmed in a multicenter study, the use of Z1 filters abolished PPR in 75.9% and a 17.9% of PPR attenuation, evaluated by increased latency between the stimulus and the appearance of PPR, reduced duration of PPR, disappearance of clinical manifestations, or change to a less severe type according to Waltz's classification in 17.9% from patients.^{4,5}

It has been previously described that 30% of patients with epilepsy have no control of their seizures, despite the use of 2 or more correctly used AEDs, considering this condition as Drug Resistant Epilepsy (DRE). Valproic acid can control photosensitivity in about 40% of cases. There are no studies

